Bausch & Lomb Sold To Valeant Pharmaceuticals For $8.7 Billion
This article was originally published in The Gray Sheet
Executive Summary
In the latest of more than a dozen acquisitions Valeant has made since it was created by a merger with Biovail SA in 2011, Valeant’s purchase of Bausch & Lomb will increase its eye care portfolio substantially.